Differential expression of metallopanstimulin/ S27 ribosomal protein in melanocytic lesions of the skin

Journal of Cutaneous Pathology

Volumn 24, Issue 9, 1997, Pages 533-542

  Santa Cruz, Daniel J ^a,b   Hamilton, Paul D ^c   Klos, Dennis J ^c   Fernandez Pol, J Albert ^c,d  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIBOSOME PROTEIN;

ARTICLE; BENIGN TUMOR; CELL DIFFERENTIATION; CELL SUBPOPULATION; CONGENITAL NEVUS; EPIDERMIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JUVENILE MELANOMA; MAJOR CLINICAL STUDY; MELANOCYTE; MELANOMA;

AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; DNA-BINDING PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MELANOMA; METALLOPROTEINS; MOLECULAR SEQUENCE DATA; NEVUS, EPITHELIOID AND SPINDLE CELL; NEVUS, PIGMENTED; NUCLEAR PROTEINS; RECURRENCE; RIBOSOMAL PROTEINS; RIBOSOMES; RNA-BINDING PROTEINS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0030679793     PISSN: 03036987     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0560.1997.tb01457.x     Document Type: Article

References (50)

1. Argenyi ZB, Cain C, Bromley C et al. S-100 protein-negative malignant melanoma: fact or fiction? A light-microscopic and immunohistochemical study. Am J Dermatopathol 1994: 16: 233.
2. Fernando SS, Johnson S, Bate J. Immunohistochemical analysis of cutaneous malignant melanoma: comparison of S-100 protein, HMB-45 monoclonal antibody and NKI/ C3 monoclonal antibody. Pathology 1994: 26: 16.
3. Smoller BR, Hsu A, Krueger J. HMB-45 monoclonal antibody recognizes an inducible and reversible melanocyte cytoplasmic protein. J Cutan Pathol 1991: 18: 315.
4. Taatjes DJ, Arendash-Durand B, von Turkovich M, Trainer TD. HMB-45 antibody demonstrates melanosome specificity by immunoelectron microscopy. Arch Pathol Lab Med 1993: 117: 264.
5. Barnhill RL, Fandrey K, Levy MA, Mihm MC Jr, Hyman B. Angiogenesis and tumor progression of melanoma. Quantification of vascularity in melanocytic nevi and cutaneous malignant melanoma. Lab Invest 1992: 67: 331.
6. Bishop PW, Menasce LP, Yates AJ, Win NA, Banerjee SS. An immunophenotypic survey of malignant melanomas. Histopathology 1993: 23: 159.
7. Boivin C, Thomine E, Menard JF, Bigorgne C, Hemet J. Morphometric analysis of melanocytic tumors. A study of nuclear area and density. Am J Dermatopathol 1994: 16: 145.
8. Bouffard D, Duncan LM, Howard CA Mihm MC Jr, Byers HR. Actin-binding protein expression in benign and malignant melanocytic proliferations. Hum Pathol 1994: 25: 709.
9. Cerroni L, Soyer HP, Keri H. bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi. Am J Dermatopathol 1995: 17: 7.
10. Danen EH, Ten Berge DJ, Van Muijen GN, Van't Hof-Grootenboer AE, Brocker EB, Ruiter DJ. Emergence of alpha 5 beta 1 fibronectin- and alpha v beta 3 vitronectin-receptor expression in melanocytic tumour progression. Histopathology 1994: 24: 249.
11. Fleming MG, Howe SF, Graf LH Jr. Expression of insulin-like growth factor I (IGF-I) in nevi and melanomas. Am J Dermatopathol 1994: 16: 383.
12. Fogt F, Vortmeyer AO, Tahan SR. Nucleolar organizer regions (AgNOR) and Ki-67 immunoreactivity in cutaneous melanocytic lesions. Am J Dermatopathol 1995: 17: 12.
13. Heinisch G, Barth J. [AgNOR expression in skin tumors. Studies of melanocytic, epidermal and fibrohistiocytic lesions]. Hautarzt 1995: 46: 177.
14. Herrintong CS, McGee JO'D. Diagnostic molecular pathology: A practical approach. Vols. I & II. New York: IRL Press at Oxford University Press, 1992.
15. Kanoko M, Ueda M, Ichihashi M. PCNA expression and nucleolar organizer regions in malignant melanoma and nevus cell nevus. Kobe J Med Sci 1994: 40: 107.
16. Korabiowska M, Brinck U, Honig J, Mora O, Bartkowski S, Schauer A. CD-44: a marker of metastases of head and neck melanomas. In Vivo 1995: 9: 253.
17. Kossard S, Wilkinson B. Nucleolar organizer regions and image analysis nuclear morphometry of small cell (nevoid) melanoma. J Cutan Pathol 1995: 22: 132.
18. Kuwata T, Kitagawa M, Kasuga T. Proliferative activity of primary cutaneous melanocytic tumors. Virchows Arch A Pathol Anat Histopathol 1993: 423: 359.
19. Lassam NJ, From L, Kahn HJ. Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res 1993: 15(Suppl): 2235.
20. Lazaris AC, Theodoropoulos GE, Aroni K, Seatta A, Davaris PS. Immunhistochemical expression of C-myc oncogene, heat shock protein 70 and HLA-DR molecules in malignant cutaneous melanoma. Virchows Arch 1995: 426: 461.
21. Levin DB, Wilson K, Valadares de Amorim G, Webber J, Kenny P, Kusser W. Detection of p53 mutations in benign and dysplastic nevi. Cancer Res 1995: 55: 4278.
22. McGregor JM, Yu CC, Dublin EA, Barnes DM, Levison DA, MacDonald DM. p53 immunoreactivity in human malignant melanoma and dysplastic naevi. Br J Dermatol 1993: 128: 606.
23. Mooney EE, Ruis Peris JM, O'Neill A, Sweeney EC. Apoptotic and mitotic indices in malignant melanoma and basal cell carcinoma. J Clin Pathol 1995: 48: 242.
24. Natali PG, Nicotra MR, Di Filippo F, Bigotti A. Expression of fibronectin, fibronectin isoforms and integrin receptors in melanocytic lesions. Br J Cancer 1995: 71: 1243.
25. Oord JJ, Vandeghinste N, De Ley M, De Wolf-Peeters C. Bcl-2 expression in human melanocytes and melanocytic tumors. Am J Pathol 1994: 145: 294.
26. Ramsay JA, From L, Kahn HJ. Bcl-2 protein expression in melanocytic neoplasms of the skin. Mod Pathol 1995: 8: 150.
27. Reed JA, McNutt NS, Albino AP. Differential expression of basic fibroblast growth factor (bFGF) in melanocytic lesions demonstrated by in situ hybridization. Implications for tumor progression. Am J Pathol 1994: 144: 329.
28. Reed JA, McNutt NS, Prieto VG, Albino AP. Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression. Am J Pathol 1994: 145: 97.
29. Saenz-Santamaria MC, Reed JA, McNutt NS, Shea CR. Immunohistochemical expression of BCL-2 in melanoma and intradermal nevi. J Cutan Pathol 1994: 21: 393.
30. Soyer HP. Ki 67 immunostaining in melanocytic skin tumors. Correlation with histologic parameters. J Cutan Pathol 1991: 18: 264.
31. Sparrow LE, Soong R, Dawkins HJ, Iacopetta BJ, Heenan PJ. p53 gene mutation and expression in naevi and melanomas. Melanoma Res 1995: 5: 93.
32. Stolz W, Vogt T, Landthaler M, Hempfer S, Bingler P, Abmayr W. Differentiation between malignant melanomas and benign melanocytic nevi by computerized DNA cytometry of imprint specimens. J Cutan Pathol 1994: 21: 7.
33. Takahashi H, Strutton GM, Parsons PG. Determination of proliferating fractions in malignant melanomas by anti-PCNA/cyclin monoclonal antibody. Histopathology 1991: 18:221.
34. Tron VA, Krajewski S, Klein-Parker H, Li G, Ho VC, Reed JC. Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma. Am J Pathol 1995: 146: 643.
35. Tuominen H, Kallionen M. Increased tenascin expression in melanocytic tumors. J Cutan Pathol 1994: 21: 424.
36. Vacca A, Ribatti D, Roncali L et al. Melanocyte tumor progression is associated with changes in angiogenesis and expression of the 67-kilodalton laminin receptor. Cancer 1993: 15: 455.
37. Zeiger B, Hittmair A, Schir M et al. Immunohistochemically demonstrated metallothionein expression in malignant melanoma. Histopathology 1993: 23: 257.
38. Fernandez-Pol JA. Modulation of EGF receptor protooncogene expression by growth factors and hormones in human breast carcinoma cells. Crit Rev Oncog 1991: 2: 173.
39. Fernandez-Pol JA, Klos DJ, Hamilton PD. Cytotoxic activity of fusaric acid on human adenocarcinoma cells in tissue culture. Anticancer Res 1993: 13: 57.
40. Fernandez-Pol JA, Klos DJ, Grant GA. Purification and biological properties of type beta transforming growth factor from mouse transformed cells. Cancer Res 1986: 46: 5153.
41. Fernandez-Pol JA, Klos DJ, Hamilton PD, Schuette VM. A transforming growth factor beta 1-induced gene encodes a novel DNA-binding protein with zinc finger structure. J Cell Biochcm 1992: 16D: 402.
42. Fernandez-Pol JA, Klos DJ, Hamilton PD, Schuette VM. A growth factor-induced gene product produced in a baculovirus expression system is a nuclear zinc-finger protein that binds to DNA. J Cell Biochem 1992: 16C: 27.
43. Fernandez-Pol JA, Klos DJ, Hamilton PD. A growth factor-inducible gene encodes a novel nuclear protein with zinc-finger structure. J Biol Chem 1993: 268: 21198.
44. Fernandez-Pol JA, Klos DJ, Hamilton PD. Metallopanstimulin gene product produced in a baculovirus expression system is a nuclear phosphoprotein that binds to DNA. Cell Growth Differ 1994: 5: 811.
45. Xynos FP, Klos DJ, Hamilton PD, Schuette V, Huygens P, Fernandez-Pol JA. Expression of metallopanstimulin in condylomata acuminata of the female anogenital region induced by papilloma virus. Anticancer Res 1994: 14: 773.
46. Fernandez-Pol JA. Metallopanstimulin as a novel tumor marker in sera of patients with various types of common cancers: Implications for prevention and therapy. Anticancer Res 1996: 16: 2177.
47. Fernandez-Pol JA. Growth factors, oncogenes and aging. In: Balducci L, Lyman GH, Henderson CC, Ershler WB, eds. Comprehensive geriatric oncology. London: Harwood Academic Publishers, 1997: 179.
48. Chan Y-L, Suzuki K, Olvera J, Wool IG. Zinc finger-like motifs in rat ribosomal proteins S27 and S29. Nuc Acids Res 1993: 21: 649.
49. Majno G, Joris I. Apoptosis, oncosis, and necrosis: An overnew of cell death. Am J Pathol 1995: 146: 3.
50. Fernandez-Pol JA, Theodoro, D, Hamilton PD, Santa Cruz DJ. Metallopanstimulin gene expression, apoptosis, and melanocytic lesions of the skin. Keystone Symposia on Molecular and Cellular Biology, Apoptosis and Programmed Cell Death. Proceedings of Symposium, Keystone Sympsia, Silverstone, Co, USA. 1997: 58A.